Does the eltrompobag treatment safe or effective for refractory chronic immune thrombocytopenia patients?

作者：Dal Mehmet Sinan^*; Karakus Abdullah; Cakar Merih Kizil; Ulu Bahar Uncu; Hattapoglu Elif; Ekmen Mehmet Onder; Ulas Turgay; Tekgunduz Emre; Altuntas Fevzi; Ayyildiz Orhan

来源：International Journal of Clinical and Experimental Medicine, 2016, 9(9): 18707-18711.

• Immune thrombocytopenia
• thrombopoietin receptor agonist
• thrombosis
• eltrombopag

Background: Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disorder characterized by immune-mediated platelet destruction and reduced platelet production. As the pathophysiology of the disease got clear, thrombopoietin receptor (TPO-R) agonists have been preferred in recent years, which seems to be an effective option in the treatment of resistant cases. Eltrombopag, a TPO-R agonist, is a second or third line medical treatment option for adults with chronic ITP. Objective: To determine the efficacy and safety of long-term eltrombopag treatment in treatment-refractory patients with primary ITP was the aim of this study. Materials and Methods: Retrospective data of 34 patients with refractory ITP who were treated with eltrombopag were examined. Efficacy and safety of the eltrombopag treatment was evaluated. Results: The total rate of response was 82%, and the median duration of response defined as the number of the platelets being over 50x10(9)/L was 14 (interquartile range: 7-28) days. In two patients, thrombosis was observed with no other additional risk factors due to or related to thrombosis. Conclusion: In spite of the fact that the responses to eltrombopag were satisfactory, patients need to be monitored closely for increasing platelet counts as well as thromboembolic events.

• 出版日期2016